NLRP3 and atherosclerosis: Furthermore, genetic inhibition of the classical IL‐6 signalling pathway due to the commonly occurring IL6R p.Asp358Ala coding mutation resulted in a 50% reduction of future ASCVD risk among carriers of CHIP clones, but not in individuals without CHIP, thereby suggesting that subjects with CHIP may be better responders to therapeutic modulation of NLRP3 inflammasome‐driven immunopathology.42